Home/Pipeline/Mogamulizumab (Poteligeo)

Mogamulizumab (Poteligeo)

Cutaneous T-cell lymphoma

ApprovedCommercial

Key Facts

Indication
Cutaneous T-cell lymphoma
Phase
Approved
Status
Commercial
Company

About Kyowa Kirin

Kyowa Kirin is a leading specialty pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on rare diseases and oncology. The company has built a robust pipeline through internal R&D capabilities and strategic partnerships, with particular expertise in antibody engineering and cell therapy technologies. Kyowa Kirin operates globally with a presence in Japan, Asia-Pacific, North America, and Europe, and is publicly traded on the Tokyo Stock Exchange.

View full company profile